What you should know about FDA Project Optimus for your oncology drug approval
Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This has resulted in drugs’ pharmacokinetic (PK) profiles, pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical target inhibition largely being ignored. Thus, cancer patients often struggle to tolerate their medication doses long-term, requiring dose modifications including dose reductions and holidays. What’s more, for many … Continued
https://www.certara.com/on-demand-webinar/what-you-should-know-about-fda-project-optimus-for-your-oncology-drug-approval/